PDF(Pubmed)
Abstract：
UNASSIGNED: Cardiovascular diseases (CVD) are leading cause of mortality in patients with type 2 diabetes mellitus (T2DM). Increased soluble sP-selectin and 715Thr > Pro polymorphism were studied in CVD and T2DM, but association between them hasn\'t been explored in Saudi Arabia. We aimed to assess sP-selectin levels in T2DM and T2DM-associated CVD patients in comparison to healthy control cohort. Also, we sought to investigate relationship between Thr715Pro polymorphism and sP-selectin levels and disease state.
UNASSIGNED: This is a cross-sectional case-control study. sP-selectin level (measured by Enzyme-linked immunosorbent assay) and prevalence of Thr715Pro polymorphism (assessed by Sanger sequencing) were investigated in 136 Saudi participants. The study comprised 3 groups: group1 included 41 T2DM patients; group 2 (48 T2DM patients with CVD), and group 3 (47 healthy controls).
UNASSIGNED: sP-selectin levels were significantly higher in diabetics and diabetics + CVD groups as compared to the corresponding control. In addition, results showed that the prevalence of 715Thr > Pro polymorphism is 11.75 % in the study population amongst the three study groups (9.55 % Thr/Pro, and 2.2 % Pro/Pro). No statistical difference was found between sP-selectin levels in subject carrying the wildtype genotype of this polymorphism and these who carry the mutant gene. There could be an association between this polymorphism and T2DM, whilst the polymorphism may protect diabetic patients from having CVD. However, odds ratio is not statistically significant in both cases.
UNASSIGNED: Our study supports the previous researches\' results that Thr715Pro is neither influencing the sP-selectin level nor the risk of CVD in T2DM patients.
UNASSIGNED: This is a cross-sectional case-control study. sP-selectin level (measured by Enzyme-linked immunosorbent assay) and prevalence of Thr715Pro polymorphism (assessed by Sanger sequencing) were investigated in 136 Saudi participants. The study comprised 3 groups: group1 included 41 T2DM patients; group 2 (48 T2DM patients with CVD), and group 3 (47 healthy controls).
UNASSIGNED: sP-selectin levels were significantly higher in diabetics and diabetics + CVD groups as compared to the corresponding control. In addition, results showed that the prevalence of 715Thr > Pro polymorphism is 11.75 % in the study population amongst the three study groups (9.55 % Thr/Pro, and 2.2 % Pro/Pro). No statistical difference was found between sP-selectin levels in subject carrying the wildtype genotype of this polymorphism and these who carry the mutant gene. There could be an association between this polymorphism and T2DM, whilst the polymorphism may protect diabetic patients from having CVD. However, odds ratio is not statistically significant in both cases.
UNASSIGNED: Our study supports the previous researches\' results that Thr715Pro is neither influencing the sP-selectin level nor the risk of CVD in T2DM patients.
摘要：
未经证实：心血管疾病(CVD)是2型糖尿病(T2DM)患者死亡的主要原因。在CVD和T2DM中研究了可溶性sP-选择素和715Thr>Pro多态性的增加，但是他们之间的联系在沙特阿拉伯还没有被探索过。我们旨在评估与健康对照组相比，T2DM和T2DM相关CVD患者的sP-选择素水平。此外，我们试图调查Thr715Pro多态性与sP-选择素水平和疾病状态之间的关系。
UNASSIGNED：这是一项横断面病例对照研究。在136名沙特参与者中调查了sP-选择素水平（通过酶联免疫吸附测定法测量）和Thr715Pro多态性的患病率（通过Sanger测序评估）。该研究包括3组：第1组包括41名T2DM患者；第2组（48名T2DM伴CVD患者），和第3组（47名健康对照）。
UNASSIGNED：糖尿病患者和糖尿病+CVD组的sP-选择素水平明显高于相应的对照组。此外,结果表明，在三个研究组中，研究人群中715Thr>Pro多态性的患病率为11.75％（Thr/Pro为9.55％，和2.2%Pro/Pro）。携带该多态性的野生型基因型的受试者和携带突变基因的受试者的sP-选择素水平之间没有发现统计学差异。这种多态性与T2DM之间可能存在关联，而多态性可能保护糖尿病患者免于CVD。然而,在这两种情况下，比值比没有统计学意义。
UNASSIGNED：我们的研究支持先前的研究结果，即Thr715Pro既不影响T2DM患者的sP-选择素水平，也不影响CVD风险。
UNASSIGNED：这是一项横断面病例对照研究。
UNASSIGNED：糖尿病患者和糖尿病+CVD组的sP-选择素水平明显高于相应的对照组。
UNASSIGNED：我们的研究支持先前的研究结果，即Thr715Pro既不影响T2DM患者的sP-选择素水平，也不影响CVD风险。
